Eat a ‘flavodiet' to stay physically and mentally strong when older, new study suggests
A diet focused on whole plant foods is a critical determinant of healthy aging.
Among the countless bioactive compounds in plants, flavonoids have received considerable attention in recent years for their influence on health.
Research suggests, for example, that a high intake of these protective phytochemicals can guard against cardiovascular disease, Type 2 diabetes, certain cancers, cognitive decline and dementia.
Now, new study findings add to mounting evidence for flavonoids' healthy-aging benefits.
The findings suggest that a high flavonoid diet – and a regular intake of specific flavonoid-rich foods – can lower the risks of developing frailty, impaired physical function and poor mental health in our 70s and beyond.
What are flavonoids?
Flavonoids are a large family of more than 5,000 phytochemicals in fruits, vegetables and other plant foods. Dietary flavonoids are categorized into six subclasses, each one residing in certain foods and having specific health properties.
The subclasses are anthocyanins (berries, red grapes, plums, red cabbage), flavan-3-ols (green and black tea, cocoa), flavonols (onions, kale, arugula, watercress), flavanones (citrus fruit), flavones (parsley, thyme, celery) and isoflavones (soybeans, lentils, chickpeas).
About the latest research
The study, published last month in the American Journal of Clinical Nutrition, investigated the relationship between intake of flavonoids and flavonoid-rich foods and frailty, impaired physical function and poor mental health, indicators of unhealthy aging.
The research team analyzed data from two U.S. studies: the Nurses' Health Study (females) and the Health Professionals Follow-up Study (males). A total of 62,743 women and 23,687 men, ages 60 and older, were followed for 24 and 12 years, respectively.
Information on age, body measurements, lifestyle behaviours, medication use, family medical history and recent personal health diagnoses was collected every two years.
Participants provided detailed dietary information at baseline and every four years thereafter. A 'flavodiet' score was calculated for each participant by adding up intakes (servings/day) of key food contributors to total flavonoid intake.
Key flavonoid-rich foods included blueberries, strawberries, grapes, raisins, apples, oranges, orange juice, grapefruit, grapefruit juice, tea, red wine, onion and sweet bell peppers.
Frailty, measured every four years, was defined as having at least three of five criteria: fatigue, poor strength, reduced aerobic capacity, at least five chronic illnesses and a weight loss of five per cent or more.
Participants reported perceived physical limitations in basic mobility, daily living tasks and performing various moderate and vigorous activities. They were also asked about symptoms of depression, anxiety and overall well-being.
High flavodiet scores protective
Among participants in the Nurses' Health Study, those with the highest flavodiet scores had a 15 per cent lower risk of developing frailty, a 12 per cent lower risk of developing impaired physical function and a 12 per cent lower risk of developing poor mental health during the study period compared to women with the lowest flavodiet scores.
The highest intakes of tea, red wine, apples, blueberries, strawberries, oranges and orange juice – and increased intakes of these foods over the study period – were associated with a lower risk of all three outcomes in women.
Surprisingly, fewer protective effects were seen in men.
Participants in Health Professionals Follow-up Study with the highest (versus lowest) flavodiet scores were 18 per cent less likely to have poor mental health scores.
Higher intakes of tea and blueberries were tied to a lower risk of poor mental health. Intakes of key flavonoid-rich foods were not associated with risk of frailty or impaired physical function.
It's unclear if there are differences in diet-related risks factors for health in aging between males and females. The findings in men may also have been influenced by the shorter follow-up of 12 years, resulting in fewer outcomes being reported.
The researchers also found that a daily increase of three servings of flavonoid-rich foods and beverages during the study translated to a 6 to 11 per cent lower risk across all three outcomes in females and a 15 per cent lower risk of poor mental health in males.
To arrive at their findings, the researchers accounted for other influential factors including age, smoking status, family health history, personal health, physical activity, body mass index and calorie intake.
How flavonoids safeguard healthy aging
The new findings are in keeping with previous studies linking high intakes of flavonoids or flavonoid-rich foods to a lower risk of frailty, impaired physical function and depression.
Flavonoids' strong antioxidant and anti-inflammatory effects are thought to protect cells from damage caused by oxidative stress and inflammation, factors that accumulate during aging.
Elevated levels of inflammation can lead to loss of muscle mass and strength.
Inflammatory immune compounds can also communicate with the brain, affecting mood and energy levels.
Takeaway
The findings suggest a modest, yet doable, dietary adjustment – increasing your daily intake of flavonoid-rich foods by three servings – can optimize healthy aging and quality of life.
One serving is equivalent to one half-cup of blueberries, strawberries or grapes, one ounce of raisins, one whole orange or apple, one half of a grapefruit, five ounces of citrus fruit juice, eight ounces of tea, one slice of raw onion or one half-cup cooked or one-quarter of a small bell pepper.
Leslie Beck, a Toronto-based private practice dietitian, is director of food and nutrition at Medcan. Follow her on X @LeslieBeckRD
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
27 minutes ago
- CBC
Measles-infected newborn baby dies in southwestern Ontario
Ontario's Ministry of Health has announced the first recorded death of a measles patient from the current outbreak that started in October. Dr. Kieran Moore, chief medical officer of health, issued a statement Thursday saying a southwestern Ontario infant has died after being born prematurely and infected with the highly contagious virus through the mother. Moore offered few other details. Southwestern Public Health, which covers Oxford and Elgin counties, confirmed the child was from a community in their coverage area. "The infant contracted the virus before birth from their mother, who had not received the measles, mumps and rubella [MMR] vaccine," Moore wrote. "While measles may have been a contributing factor in both the premature birth and death, the infant also faced other serious medical complications unrelated to the virus. "Out of respect for the family's privacy, no further personal or medical details will be shared." The death is the first in this outbreak, which at last count, on Tuesday, included up 2009 probable and confirmed cases since it began on Oct. 28, according to the ministry. It's only the second measles-related death the province has seen in decades, after an unvaccinated child from Hamilton who was younger than five years old died in May 2024. Current outbreak traced to wedding Previously, Moore shared that this outbreak in Ontario was traced back to a Mennonite wedding in New Brunswick, and is spreading primarily in Mennonite and Amish communities where vaccination rates lag. The vast majority of those cases are in southwestern Ontario. The official case count in the current outbreak is likely lower than the actual number as many cases aren't being reported, health officials have said. Case counts have been highest in the areas covered by Southwestern Public Health, Chatham-Kent Public Health, Huron-Perth Public Health, Grand Erie Public Health and the Windsor-Essex County Health Unit. In May alone, 79 people were diagnosed with measles by Southwestern Public Health, which by far has the largest case count in the province. Seventy-five per cent of patients in that health unit were younger than 18. Those most at risk from the measles virus are unvaccinated children, health officials have warned throughout the outbreak. "Measles poses a serious risk to unvaccinated individuals and to infants in the early stages of life in particular," Moore wrote in the release Thursday. "Anyone who is unvaccinated is at risk and I urge everyone, but especially those who may become pregnant, to ensure they have received two doses of the MMR vaccine, which will protect both a parent and baby. This vaccine has been safely used for over 50 years and is highly effective. Two doses provide nearly 100 per cent protection." Officials in public health areas affected by the outbreak have told reporters they've poured resources into delivering that message to rural communities in different languages and through outreach to faith leaders. Moore said measles is one of the most contagious known diseases. Complications from infection can include pneumonia, brain swelling, premature birth and death. Those seeking vaccination are urged to contact their local health units.


Globe and Mail
32 minutes ago
- Globe and Mail
$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
$NRXP Has $7.8 Million in Financing for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). Abbreviated New Drug Application Filed for Preservative-Free IV Ketamine. Current Ketamine Market Estimated at $750 Million and Projected to Reach $3.35 Billion Globally in 2034. $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions with Universal Capital, LLC. Added to Previously Announced Term Sheet with a Strategic Investor, NRXP HOPE Funding of $10.3 Million is Planned in Near Term. Agreement to Purchase Kadima Neuropsychiatry Institute Expected to Serve as Clinical Model for Treatment Offerings Nationwide. Kadima is a Leading Investigative Site for CNS and Psychedelic Research, Having Served as the Lead Site in Nearly All Major Trials in This Space. Dr. David Feifel, Nationally Recognized Pioneer in Interventional Psychiatry to join as Chief Medical Innovation Officer. New Drug Application for Treatment of Suicidal Depression; Planned NDA for Accelerated Approval for Bipolar Depression in People at Risk of Akathisia. Patent Application Filed for NRX-100 Proprietary, Preservative Free Formulation of IV Ketamine. Patent expected to be Orange Book Listable. Waiver Exemption from Paying a $4.3 Million New Drug Application Fee Under Prescription Drug User Fee Act (PDUFA). Accepted Non-Binding Potential Terms to License and Distribute NRX-100 Drug Providing Over $300 Million in Milestones Plus Tiered Double-Digit Royalties. Application to Uplist to NASDAQ Global Market from NASDAQ Capital Market NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100. In a January 2025 report, respected investment analysis firm D. Boral Capital assigned NRXP a $31 Price Target. The full report may be viewed at this link: Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine On June 5th NRXP announced the transmission of its Abbreviated New Drug Application (ANDA) for electronic filing to the U.S. Food and Drug Administration (FDA) for NRX-100, its preservative-free IV ketamine formulation, for use in all existing approved indications such as anesthesia and pain management. NRXP anticipates filing a citizen's petition with the FDA to remove benzethonium chloride, a known neurotoxic and cytotoxic substance, from presentations of ketamine intended for intravenous use. NRXP believes that the preservative-free feature of NRX-100 will be deemed of benefit to patients because of the known toxicity of closely related benzalkonium chloride in current drug products. Preservatives were originally added to sterile injectable products in an era when a single vial of medication was used to treat multiple patients, a practice no longer allowed in US hospitals. NRXP has demonstrated that there is no need for such preservatives to maintain stability and sterility in ketamine presentations intended for single-patient use. Should the citizen's petition be granted, all formulations of ketamine sold in the US could face a regulatory requirement to be preservative free. $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions On May 15th NRXP announced signing of a term sheet with Universal Capital, LLC to provide $7.8 million in acquisition capital to initiate subsidiary HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital. HOPE's three initial acquisitions represent best-in-class clinics that offer neuroplastic treatments including NRXP ketamine and transcranial magnetic stimulation (TMS) to treat patients with severe depression, PTSD, and related central nervous system conditions. Neuroplastic treatments represent a rapidly emerging class of interventions that cause the growth of new connections (synapses) between brain cells that have been shown in multiple clinical trials to relieve symptoms of depression and suicidality. The FDA has approved TMS devices for a number of indications and has approved a nasal form of ketamine for treatment resistant depression. HOPE's parent company, NRXP, is currently applying to the FDA for approval of intravenous preservative-free ketamine to treat suicidal depression. Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the NRXP HOPE Network of Interventional Psychiatry Clinics On May 13th NRXP announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in NRXP HOPE-acquired clinics and is expected to continue its role as a leading investigative site for research into neuroplastic therapies including psychedelic medications, transcranial magnetic stimulation (TMS), and hyperbaric therapy. Kadima is one of California's flagship interventional psychiatry clinics and was among the first to bring ketamine treatment for central nervous system (CNS) disorders out of academic research settings and into clinical practice. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, transcranial magnetic stimulation ("TMS") as well as medication management. Further, Kadima and David Feifel, MD PhD, Founder and Medical Director of Kadima, have served as leaders in clinical trial work on emerging therapies in CNS for top companies in the industry. Importantly, the clinic is profitable and is forecast to continue growth going forward. Dr. Feifel will join NRXP HOPE as its first Chief Medical Innovation Officer upon closing of the acquisition. Patent Application Filed for NRX-100 Proprietary, Preservative Free Formulation of IV Ketamine On May 5th NRXP announced the filing of a patent application for NRX-100, its preservative-free intravenous ketamine formulation for the treatment of suicidal depression. The application discloses pharmaceutical compositions, methods of treatment and methods of manufacture and currently includes twenty claims. While subject to the patent review process of the US Patent and Trademark Office, if granted, the patent would provide NRX-100 exclusivity into 2045. This patent filing builds on the NRXP recently initiated filing of an NDA for NRX-100 and its prior Fast Track Designation, with NRX-101, from the FDA. If granted, the patent will help protect the innovation behind this formulation as NRXP advances its commercialization strategy. "We are committed to delivering safer, more effective treatments for patients with suicidal depression," said Jonathan Javitt MD MPH, CEO of NRXP. "NRX-100 eliminates the need for benzethonium chloride, a compound with well-documented safety concerns, and reflects our belief that patients in crisis deserve therapies formulated with their long-term well-being in mind. With the recent FDA fee waiver now in place, we remain on track to complete our NDA submission this quarter — a critical step toward bringing this innovation to patients in need." FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression On April 30th NRXP announced the grant of a filing fee waiver by the US Food and Drug Administration ("FDA") to exempt the Company from a $4.3 million fee to file its New Drug Application for NRX-100 (preservative-free ketamine). The waiver is granted at the discretion of the FDA to Small Business Entities and for drugs that are deemed to be necessary for Public Health. NRXP anticipates that this waiver enables the completion of its New Drug Application for NRX-100 with currently-available corporate resources. The NDA filing is anticipated by the end of the second quarter of this year (Q2 2025). Disclosure listed on the CorporateAds website Media Contact Company Name: NRx Pharmaceuticals, Inc. Contact Person: Matthew Duffy, Chief Business Officer Email: Send Email Phone: 484 254 6134 Address: 1201 Orange Street Suite 600 City: Miami State: Florida Country: United States Website:


CBC
an hour ago
- CBC
Measles-infected infant dies in southwestern Ontario
Ontario's Ministry of Health announced on Thursday the first recorded death of a measles patient from the current outbreak that started in October of last year. Dr. Kieran Moore, Ontario's chief medical officer of health, issued a statement announcing the death of a southwestern Ontario infant that was born prematurely and infected with the highly contagious virus through its mother, but offered few details. "The infant contracted the virus before birth from their mother, who had not received the measles, mumps and rubella [MMR] vaccine. While measles may have been a contributing factor in both the premature birth and death, the infant also faced other serious medical complications unrelated to the virus," Moore wrote. "Out of respect for the family's privacy, no further personal or medical details will be shared."